ReNcell VM is an immortalized human neural progenitor cell line with the ability to readily differentiate into neurons and glial cells. ReNcell VM was derived from the ventral mesencephalon region of human fetal brain. Immortalized by retroviral transduction with the v-myc oncogene, this cell line grows rapidly as a monolayer on laminin with a doubling time of 20-30 hours. Karyotype analyses indicate that the ReNcell VM retains a normal diploid karyotype in culture even after prolonged passage (45 passages). ReNcell VM was developed by the ReNeuron Group plc, a biotech company that specializes in using human somatic stem cells for therapeutics. In experiments performed by the ReNeuron Group plc, ReNcell VM can be differentiated in vitro to a high level of human dopaminergic neurons. Neurons differentiated from ReNcell VM have furthermore been shown to be electophysiologically active. ReNcell VM may be used for a variety of research applications such as studies of neurotoxicity, neurogenesis, electrophysiology, neurotransmitter and receptor functions. ReNcell VM cells have been obtained in a legal and ethical manner, compliant with current local informed consent procedures.